Leland Gershell
Stock Analyst at Oppenheimer
(4.58)
# 229
Out of 5,090 analysts
145
Total ratings
51.45%
Success rate
32.73%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $13.57 | +76.93% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $8.18 | +303.42% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $6.72 | +168.06% | 5 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $32.49 | +10.82% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $47.47 | +83.27% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $21.24 | +276.65% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $52.71 | +108.69% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $74.74 | -18.38% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $464.56 | +5.48% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $9.06 | +120.87% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $106.01 | +3.77% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 → $22 | $25.51 | -13.74% | 5 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $208.09 | +7.65% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $24.14 | +28.42% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.72 | +481.40% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $916.31 | -22.73% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.59 | +178.55% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $53.82 | +82.11% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $44.90 | +15.83% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.44 | +1,949.18% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $22.94 | +131.04% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.80 | +215.79% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $4.42 | +112,899.46% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $6.85 | +264.96% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $4.65 | +330.11% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $23.14 | +25.35% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $18.01 | +94.39% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.56 | +1,701.15% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $0.90 | +2,111.78% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.63 | +394.30% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.79 | +3,070.41% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.32 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $28.41 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.98 | +5,011.17% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $16.48 | - | 5 | Mar 31, 2020 |
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $13.57
Upside: +76.93%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $8.18
Upside: +303.42%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $6.72
Upside: +168.06%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $32.49
Upside: +10.82%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $47.47
Upside: +83.27%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $21.24
Upside: +276.65%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $52.71
Upside: +108.69%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $74.74
Upside: -18.38%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $464.56
Upside: +5.48%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $9.06
Upside: +120.87%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $106.01
Upside: +3.77%
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $25.51
Upside: -13.74%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $208.09
Upside: +7.65%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $24.14
Upside: +28.42%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.72
Upside: +481.40%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $916.31
Upside: -22.73%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $3.59
Upside: +178.55%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $53.82
Upside: +82.11%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $44.90
Upside: +15.83%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.44
Upside: +1,949.18%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $22.94
Upside: +131.04%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.80
Upside: +215.79%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $4.42
Upside: +112,899.46%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $6.85
Upside: +264.96%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $4.65
Upside: +330.11%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $23.14
Upside: +25.35%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $18.01
Upside: +94.39%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.56
Upside: +1,701.15%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $0.90
Upside: +2,111.78%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.63
Upside: +394.30%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.79
Upside: +3,070.41%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.32
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $28.41
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $0.98
Upside: +5,011.17%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $16.48
Upside: -